{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:42:05Z","timestamp":1785822125426,"version":"3.56.0"},"reference-count":39,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T00:00:00Z","timestamp":1665964800000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare real-world effectiveness and safety of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation (AFib) for prevention of stroke.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study design and setting<\/jats:title><jats:p>A comparative cohort study in UK general practice data from The Health Improvement Network database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants and interventions<\/jats:title><jats:p>Before matching, 5655 patients \u226518 years with nonvalvular AFib who initiated at least one DOAC between 1 July 2014 and 31 December 2020 were included. DOACs of interest included apixaban, rivaroxaban, edoxaban and dabigatran, with the primary comparison between apixaban and rivaroxaban. Initiators of DOACs were defined as new users with no record of prescription for any DOAC during 12 months before index date.<\/jats:p><\/jats:sec><jats:sec><jats:title>Primary and secondary outcome measures<\/jats:title><jats:p>The primary outcome was stroke (ischaemic or haemorrhagic). Secondary outcomes included the occurrence of all-cause mortality, myocardial infarction (MI), transient ischaemic attacks (TIA), major bleeding events and a composite angina\/MI\/stroke (AMS) endpoint.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Compared with rivaroxaban, patients initiating apixaban showed similar rates of stroke (HR: 0.93; 95%\u2009CI 0.64 to 1.34), all-cause mortality (HR: 1.03; 95%\u2009CI 0.87 to 1.22), MI (HR: 0.95; 95%\u2009CI 0.54 to 1.68), TIA (HR: 1.03; 95%\u2009CI 0.61 to 1.72) and AMS (HR: 0.96; 95%\u2009CI 0.72 to 1.27). Apixaban initiators showed lower rates of major bleeding events (HR: 0.60; 95%\u2009CI 0.47 to 0.75).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Among patients with nonvalvular AFib, apixaban was as effective as rivaroxaban in reducing rate of stroke and safer in terms of major bleeding episodes. This head-to-head comparison supports conclusions drawn from indirect comparisons of DOAC trials against warfarin and demonstrates the potential for real-world evidence to fill evidence gaps and reduce uncertainty in both health technology assessment decision-making and clinical guideline development.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2022-064662","type":"journal-article","created":{"date-parts":[[2022,10,17]],"date-time":"2022-10-17T15:22:01Z","timestamp":1666020121000},"page":"e064662","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3571-3345","authenticated-orcid":false,"given":"Ashley","family":"Jaksa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seamus","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Rowark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Duffield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuj","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Kincaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayad K","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda R","family":"Patrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Govil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pall","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolle","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,10,17]]},"reference":[{"key":"2022110202400514000_12.10.e064662.1","unstructured":"GOV.UK . Atrial fibrillation prevalence estimates for local populations. Available: https:\/\/www.gov.uk\/government\/publications\/atrial-fibrillation-prevalence-estimates-for-local-populations"},{"key":"2022110202400514000_12.10.e064662.2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/ehjqcco\/qcaa093","article-title":"Atrial fibrillation in the UK: predicting costs of an emerging epidemic recognizing and forecasting the cost drivers of atrial fibrillation-related costs","volume":"8","author":"Burdett","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2022110202400514000_12.10.e064662.3","doi-asserted-by":"crossref","unstructured":"Fohtung RB . Identification of patients at risk of stroke from atrial fibrillation, 2016. Available: https:\/\/www.uscjournal.com\/articles\/identification-patients-risk-stroke-atrial-fibrillation","DOI":"10.15420\/usc.2016:1:1"},{"key":"2022110202400514000_12.10.e064662.4","first-page":"1764","article-title":"Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation","volume":"21","author":"Boriani","year":"2019","journal-title":"Europace"},{"key":"2022110202400514000_12.10.e064662.5","unstructured":"NICE . Atrial fibrillation: diagnosis and management, 2021. Available: https:\/\/www.nice.org.uk\/guidance\/ng196"},{"key":"2022110202400514000_12.10.e064662.6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013267"},{"key":"2022110202400514000_12.10.e064662.7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5058"},{"key":"2022110202400514000_12.10.e064662.8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.112.965988"},{"key":"2022110202400514000_12.10.e064662.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2015.05.018"},{"key":"2022110202400514000_12.10.e064662.10","unstructured":"U.S. Food and Drug Administration . Considerations for the use of real-world data and real-world evidence to support regulatory decision-making for drug and biological products, 2021. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-use-real-world-data-and-real-world-evidence-support-regulatory-decision-making-drug"},{"key":"2022110202400514000_12.10.e064662.11","unstructured":"Veradigm . Using Veradigm\u2019s EHR Dataset to Replicate ROCKET-AF Clinical Trial, 2021. Available: https:\/\/veradigm.com\/veradigm-news\/ehr-dataset-to-replicate-rocket-af-clinical-trial\/"},{"key":"2022110202400514000_12.10.e064662.12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051718"},{"key":"2022110202400514000_12.10.e064662.13","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13814"},{"key":"2022110202400514000_12.10.e064662.14","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1161\/STROKEAHA.120.028825","article-title":"Comparative safety and effectiveness of oral anticoagulants in nonvalvular atrial fibrillation: the Naxos study","volume":"51","author":"Van Ganse","year":"2020","journal-title":"Stroke"},{"key":"2022110202400514000_12.10.e064662.15","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/pds.4034","article-title":"Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care","volume":"25","author":"Gorst-Rasmussen","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022110202400514000_12.10.e064662.16","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1001\/jama.2021.21222","article-title":"Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation","volume":"326","author":"Ray","year":"2021","journal-title":"JAMA"},{"key":"2022110202400514000_12.10.e064662.17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/cpt.1480","article-title":"A structured Preapproval and postapproval comparative study design framework to generate valid and transparent real-world evidence for regulatory decisions","volume":"106","author":"Gatto","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"2022110202400514000_12.10.e064662.18","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"2022110202400514000_12.10.e064662.19","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1335"},{"key":"2022110202400514000_12.10.e064662.20","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2203"},{"key":"2022110202400514000_12.10.e064662.21","doi-asserted-by":"publisher","DOI":"10.14236\/jhi.v19i4.820"},{"key":"2022110202400514000_12.10.e064662.22","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-021-02416-4"},{"key":"2022110202400514000_12.10.e064662.23","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-1584"},{"key":"2022110202400514000_12.10.e064662.24","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwy049"},{"key":"2022110202400514000_12.10.e064662.25","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697"},{"key":"2022110202400514000_12.10.e064662.26","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jclinepi.2021.08.028","article-title":"Causal analyses of existing databases: no power calculations required","volume":"144","author":"Hern\u00e1n","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"2022110202400514000_12.10.e064662.27","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/sim.6377","article-title":"High-Dimensional propensity score algorithm in comparative effectiveness research with time-varying interventions","volume":"34","author":"Neugebauer","year":"2015","journal-title":"Stat Med"},{"key":"2022110202400514000_12.10.e064662.28","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181d61eeb"},{"key":"2022110202400514000_12.10.e064662.29","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.113.000359"},{"key":"2022110202400514000_12.10.e064662.30","unstructured":"OpenPrescribing. Available: https:\/\/openprescribing.net\/analyse\/ [Accessed 12 Apr 2022]."},{"key":"2022110202400514000_12.10.e064662.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"2022110202400514000_12.10.e064662.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"2022110202400514000_12.10.e064662.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907"},{"key":"2022110202400514000_12.10.e064662.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561"},{"key":"2022110202400514000_12.10.e064662.35","unstructured":"NHS Digital . Quality and Outcomes Framework (QOF), enhanced services and core contract extraction specifications (business rules). Available: https:\/\/digital.nhs.uk\/data-and-information\/data-collections-and-data-sets\/data-collections\/quality-and-outcomes-framework-qof"},{"key":"2022110202400514000_12.10.e064662.36","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1919"},{"key":"2022110202400514000_12.10.e064662.37","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-031342"},{"key":"2022110202400514000_12.10.e064662.38","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2018-312977"},{"key":"2022110202400514000_12.10.e064662.39","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k1717"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-064662","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T09:40:26Z","timestamp":1667382026000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-064662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":39,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,17]]},"published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1136\/bmjopen-2022-064662"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-064662","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}